These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 25224562)

  • 1. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
    Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer.
    Nakashoji A; Hayashida T; Yokoe T; Maeda H; Toyota T; Kikuchi M; Watanuki R; Nagayama A; Seki T; Takahashi M; Abe T; Kitagawa Y
    Cancer Treat Rev; 2018 Jan; 62():9-17. PubMed ID: 29127857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
    J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
    Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
    Baselga J; Bradbury I; Eidtmann H; Di Cosimo S; de Azambuja E; Aura C; Gómez H; Dinh P; Fauria K; Van Dooren V; Aktan G; Goldhirsch A; Chang TW; Horváth Z; Coccia-Portugal M; Domont J; Tseng LM; Kunz G; Sohn JH; Semiglazov V; Lerzo G; Palacova M; Probachai V; Pusztai L; Untch M; Gelber RD; Piccart-Gebhart M;
    Lancet; 2012 Feb; 379(9816):633-40. PubMed ID: 22257673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
    Valachis A; Nearchou A; Lind P; Mauri D
    Breast Cancer Res Treat; 2012 Oct; 135(3):655-62. PubMed ID: 22875745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HER2-positive breast cancer: standard and double targeted therapy].
    Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
    Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
    Hicks M; Macrae ER; Abdel-Rasoul M; Layman R; Friedman S; Querry J; Lustberg M; Ramaswamy B; Mrozek E; Shapiro C; Wesolowski R
    Oncologist; 2015 Apr; 20(4):337-43. PubMed ID: 25732265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
    Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
    J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.
    Wang C; Chen J; Xu X; Hu X; Kong D; Liang G; Wang X
    Technol Cancer Res Treat; 2020; 19():1533033820960721. PubMed ID: 32990165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
    Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
    Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
    Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.